Department of Pharmacy, University of Rajshahi, Rajshahi-6205, Bangladesh.
Pharmacogenomics. 2021 Apr;22(6):375-381. doi: 10.2217/pgs-2020-0096. Epub 2021 Mar 24.
Lopinavir and ritonavir are substrates of permeability glycoprotein encoded by The efficacy and safety of these drugs is unknown in COVID-19 patients affected by genetic variability. Patients carrying one or two copies of the C3435T were predictively considered as risk phenotypes. It was predicted that risk phenotypes due to carrying either one or two copies of C3435T were highly prevalent in Europe (76.8%; 95% CI: 75-78), followed by America (67%; 95% CI: 65-69), Asia (63.5%; 95% CI: 62-65) and Africa (41.4%; 95% CI: 37-46), respectively. It is hypothesized that a considerable proportion of COVID-19 patients treated with lopinavir/ritonavir inheriting C3435T genetic polymorphism may be predisposed to either therapeutic failure or toxicity.
洛匹那韦和利托那韦是由多药耐药相关蛋白基因编码的底物，在感染 COVID-19 的患者中，其疗效和安全性尚不清楚。 遗传变异会影响这些药物的效果。 携带一个或两个 C3435T 拷贝的患者被预测为风险表型。 预测携带一个或两个 C3435T 拷贝的风险表型在欧洲非常普遍（76.8%；95%CI：75-78），其次是美洲（67%；95%CI：65-69）、亚洲（63.5%；95%CI：62-65）和非洲（41.4%；95%CI：37-46）。 据推测，接受洛匹那韦/利托那韦治疗的 COVID-19 患者中，相当一部分遗传了 C3435T 基因多态性，可能容易出现治疗失败或毒性。
